Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Shares Outstanding (Diluted Average) (2016 - 2025)

Vanda Pharmaceuticals' Shares Outstanding (Diluted Average) history spans 17 years, with the latest figure at $58.9 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 1.34% to $58.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $58.9 million, a 1.34% increase, with the full-year FY2025 number at $58.9 million, up 1.34% from a year prior.
  • Shares Outstanding (Diluted Average) hit $58.9 million in Q4 2025 for Vanda Pharmaceuticals, roughly flat from $58.9 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for VNDA hit a ceiling of $59.0 million in Q2 2025 and a floor of $56.1 million in Q1 2022.
  • Historically, Shares Outstanding (Diluted Average) has averaged $57.5 million across 5 years, with a median of $57.5 million in 2023.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): rose 3.14% in 2021 and later decreased 0.74% in 2022.
  • Tracing VNDA's Shares Outstanding (Diluted Average) over 5 years: stood at $56.9 million in 2021, then grew by 0.11% to $57.0 million in 2022, then grew by 1.01% to $57.6 million in 2023, then increased by 1.03% to $58.1 million in 2024, then grew by 1.34% to $58.9 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for VNDA at $58.9 million in Q4 2025, $58.9 million in Q3 2025, and $59.0 million in Q2 2025.